Kandoset (Amlodipine, Candesartan Cilexetil)

Kandoset, a fixed‑dose combination antihypertensive, is indicated for conditions involving elevated arterial pressure.

• Hypertension: achieves sustained reduction of systolic and diastolic blood pressure in adults.
• Essential hypertension: provides additive blood pressure control when monotherapy is insufficient.
• Primary hypertension: helps patients reach target blood pressure levels recommended by clinical guidelines.

• Amlodipine blocks L‑type calcium channels in vascular smooth muscle, causing arterial relaxation and reduced peripheral resistance. Candesartan cilexetil is a pro‑drug that is converted to candesartan, an angiotensin II type 1 (AT1) receptor antagonist, preventing angiotensin‑II‑mediated vasoconstriction and aldosterone release. The complementary actions produce an additive antihypertensive effect, lowering both systolic and diastolic pressures.

Common Side Effects

• Peripheral edema: swelling of the ankles or feet.
• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness of the skin.
• Dizziness or light‑headedness, especially after standing.
• Fatigue: feeling unusually tired.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Hyperkalemia: high potassium levels that can affect heart rhythm.
• Renal impairment: worsening kidney function, especially in patients with pre‑existing disease.
• Myocardial infarction: rare reports of heart attack in susceptible individuals.

Patients should be evaluated for cardiovascular and renal status before initiating therapy.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in the elderly.
• Electrolyte surveillance: monitor potassium levels when combined with potassium‑sparing agents.
• Hepatic impairment: use with caution in patients with moderate to severe liver disease.
• Pregnancy and lactation: discuss risks with a healthcare professional before use.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Drug interactions may alter the efficacy or safety of Kandoset and should be reviewed by a prescriber.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase amlodipine exposure.
• Aliskiren in diabetic patients: heightened risk of renal impairment and hyperkalemia.
• Concurrent use of other ARBs or ACE inhibitors: may cause additive hypotensive effects and hyperkalemia.

Moderate Interactions (Monitor Closely)

• Simvastatin >20 mg: increased risk of myopathy when combined with amlodipine.
• Lithium: potential for increased lithium levels and toxicity.
• NSAIDs: may reduce antihypertensive effect and affect renal function.